WO2020144591A2

WO2020144591A2 - Preparation of purified withanoside x from withania somnifera plant materials and its medicinal use for the treatment of health disorders

Info

Publication number: WO2020144591A2
Application number: PCT/IB2020/050114
Authority: WO
Inventors: Antony Benny
Original assignee: Antony Benny
Priority date: 2019-01-09
Filing date: 2020-01-08
Publication date: 2020-07-16
Also published as: WO2020144591A3

Abstract

The invention relates to a delivery system for Withania somnifera composition, the core is characterised by a solid bead and a layer of Withanias omnifera extract covering said solid bead in a dosage form. It comprises of a core characterised by a solid bead made of any one or more compound selected from the group of Sugars, oligosaccharides, polysaccharides and their derivatives, a layer of Withania somnifera extract covering said solid bead, and a layer of protective system, so that it protects the Withania somnifera extract from acidic environment of gastric juice in a stomach. The dose form comprises 5% to 20% withanolide glycoside by weight while Withania somnifera extract is standardised with 2% to 35% withanolide glycoside by weight. Method of preparing Withania somnifera extract as well as methodof preparation of dosage form of Withania somnifera composition is disclosed here. Withania somnifera Composition is effective in reducing stress, anxiety, depression, and sleep deprivation.

Description

PREPARATION OF PURIFIED WITHANOSIDE X FROM WITHANIA SOMNIFERA PLANT MATERIALS AND ITS MEDICINAL USE FOR THE TREATMENT OF HEALTH DISORDERS

FIELD OF INVENTION The invention relates to medicinal preparation characterized by particular physical form for sustained, enteric or differential release type, and containing discrete particles with coatings of different thicknesses or different materials. The preparation characterized of Withania somnifera (Ashwagandha) extract and purified compound. More specifically, a delivery system for Withania somnifera composition derived from Withania somnifera extract in a dosage form.The present invention also relates to modifying nutritive qualities of Dietetic products; Preparation or treatment thereof using additives, plant extracts, plant sterols or derivatives thereof.

BACKGROUND OF THE INVENTION

Quality of life is assessed on a few established parameters, some of which are Stress, sleep, fatigue, and anxiety. If one suffers from Sleep deprivation, fatigue, stress or anxiety and chooses to ignore them, it may lead to severe health disorder in future. In most cases, the symptoms described above are linked to one another, and most the patients show all of the symptoms at some degree.

Among herbs Withania somnifera is known to be a natural adaptogen and a natural aphrodisiac. Withania somnifera (L.) Dunal belonging to family Solanaceae is used as a medicinal plant in the Indian traditional system. Metabolites identified from the plant species especially withanolides have been received considerable attention worldwide from scientific as well as industrial sectors due to their versatile biological activities. In addition, different classes of withanosides, glyco withanolides, sitoindosides, alkaloids, saponins, amino acids, phenolic compounds, flavonoids have also been reported in Withania somnifera. There have been attempts to identify and purify active metabolites but not much success has been achieved. Most products in market are raw extract with no significant activity being reported. This might probably be because of poor bioavailability of Withania somnifera extract. Hence what we require is a Withania somnifera based pharmaceutical product that can give consistent results. This can be achieved by developing a new delivery method and/or enriching essential active ingredients from the raw extract of Withania somnifera.

Raw extract of Withania somnifera has poor bioavailability moreover raw extracts are not standardized. The US application 20130071435 and the US patent 8597697 uses standard raw extracts in their formulations, even the US patent 7318938 is just a blend of a raw extract with maltodextrin. Another aspect is the targeted delivery of the Withania somnifera actives can give significant results. A delivery method is required, which is effective and flexible enough to be used in multiple-dose forms. US patent 8636985 uses gum as a delivery method, gum as a delivery form cannot achieve relevant activity for Withania somnifera to be considered for the treatment of stress and neurological disorder.

Of all the withanoside found in Withania somnifera some of them are extremely potent in treatment of mental illness, a composition is required to enrich such potent compounds. Withania somnifera Products available at present do not focus on improving the quality of life of people by treating stress, sleep, fatigue, and anxiety.

The problem of poor bioavailability is addressed by providing Withania somnifera in beadlet form. Targeted delivery of Withania somnifera beadlet will increase the bioavailability.

SUMMARY

The invention pertains to a dose form containing Withania somnifera composition. The dosage form comprises a core, and the core is characterized by a solid bead and a layer of Withania somnifera extract covering said solid bead, and a layer of a protective system over the said core.Withania somnifera composition comprises of 80 part methanol extract of Withania somnifera, 4.2 part HPMC, lpart talc by weight. The protective system is such that it protects the Withania somnifera composition from the acidic environment, more precisely from the gastric juice in the stomach.

In one embodiment, the Withania somnifera extract used in the dose form is standardized with 2% to 35% withanolide glycoside by weight. The withanolide glycoside is standardized with 0.5-10% withanoside X. In another embodiment, Withania somnifera composition of the dose form has one or more excipient in it. The Withania somnifera composition contains excipient and a hydro-alcoholic extract of Withania somnifera plant parts. The excipient could be an edible substance like HPMC, polyethylene glycol, talc, magnesium stearate, or PVP K30. In yet another embodiment, solid bead is made of any one or more compound selected from the group of sugars, oligosaccharides, polysaccharides and their derivatives, for example, glucose, rhamnose, galactose, lactose, sucrose, mannitol, sorbitol, dextrin, maltodextrin, cellulose, Sodium carboxymethyl cellulose, starches and a combination thereof. In another embodiment delivery system is a solid spheroidal, and the solid spheroidal is about 0.15 to 0.6 mm.

In one embodiment the protective system is made of one or more material selected from the group of; Methacrylic acid co-polymers, poly (methacrylic acid co-methyl methacrylate), poly (methacrylic acid co-ethyl acrylate), poly (methyl methacrylate-co-methacrylic acid), Cellulose acetate phthalate, polyvinyl acetate phthalate, shellac, Cellulose acetate trimellitate, Hydroxypropyl methylcellulose phthalate and combination thereof.

In yet another embodiment the protective system also contains plasticizer, and the plasticizers are selected from a group of polyethylene glycols PEG, propylene glycol, glycerol (glycerin), phthalate esters, dibutylsebacete, fractionated coconut oil, acetylated monoglycerides, and combination thereof. In yet another embodiment, the dose form has a sub coating layer between the core and protective system. The sub coat physically separates the acid labile drug from the acidic protective system, and hence improves the stability of the formulation. The sub coating is selected from a group of hydroxyl propyl methyl cellulose (HPMC), ethyl cellulose, hydroxpropyl cellulose, hydroxymethyl cellulose, cellulose acetate phthalate, and combination thereof.

In yet another embodiment, a dose form for Withania somnifera composition is characterized by a sugar beadlet, the sugar beadlet is covered with Withania somnifera composition to form a Withania beadlet core, the core is covered with HPMC to form a sealed core, and the sealed core is covered with protective system comprising Methacrylic acid co-polymers. In yet another embodiment is the extraction and purification of withanolide glycoside are disclosed. A hydroalcoholic extract of Withania somnifera plant parts is fractionated with solvents. Solvents such as methanol, acetonitrile or ethanol to churn out an elute with 35% withanolide glycoside. In yet another embodiment, the dose form for Withania somnifera composition is clinically effective in reducing stress, anxiety, depression, and sleep deprivation when the dose form is administered regularly to a person in need. The dose form is to be administered for 4 to 8 weeks to see a notable improvement in endurance, immunomodulatory activity, stress, anxiety, fatigue, depression, and sleep deprivation. BRIEF DESCRIPTION OF DRAWINGS

The above objectives and advantages of the disclosed teachings will become more apparent by describing in detail preferred embodiments thereof with reference to the attached drawings in which:

FIG.l (Part 1 and Part 2) provides a method of preparation of Withania somnifera composition according to a preferred embodiment under the invention.

FIG.2 provides a method of preparation of Protective composition of Withania somnifera extract.

FIG.3 (Part 1 and Part 2) provides a method of preparation of Withania somnifera composition according to another embodiment under the invention. FIG.4 provides AMS total score, POMS fatigue- inertia score and POMS Vigor Activity score after administering placebo and drug (the protective composition of Withania somnifera extract).

FIG.5 provides Cortisol and DHEA-S level after administering placebo and drug (the protective composition of Withania somnifera composition). FIG.6 provides Testosterone level and Estradiol level after administering placebo and drug (the protective composition of Withania somnifera composition). FIG.7 provides HAM -A score and DASS-21 score after administering placebo and drug (the protective composition of Withania somnifera composition).

FIG.8 provides Cortisol, DHEA-S and Testosterone level after administering placebo and drug (the protective composition of Withania somnifera composition). FIG.9 provides Restorative Sleep Questionnaire (RSQ-W) score after administering placebo and drug (the protective composition of Withania somnifera composition).

FIG.10 provides Sleep efficiency (SE) and Total Sleep Time (TST) after administering placebo and drug (the protective composition of Withania somnifera composition).

FIG.11 provides Sleep Onset Latency (SOL), Average awakening time and Wakefulness after Sleep Onset (WASO) after administering placebo and drug (the protective composition of Withania somnifera composition).

FIG.12 provides World health organisation- the quality of life- Bref Domain after administering placebo and drug (the protective composition of Withania somnifera composition). DETAILED DESCRIPTION OF THE INVENTION

According to the invention, a dose form containing Withania somnifera composition comprises a core, the core is characterised by a solid bead and a layer of Withania somnifera extract covering said solid bead, and a layer of protective system over the said core.A pharmaceutically active component, withanoside X derived from Withania somnifera (Ashwagandha) is also disclosed. A composition of Withania somnifera where the composition of the extract is manipulated to enrich withanolide glycosides. The enriched withanolide glycosides include withanoside X as the principal active constituent. Withania somnifera extract is characterized with 2% to about 80% withanolide glycoside. Purified active compound from Withania somnifera is characterized with at least about 95% withanoside X. Withania somnifera extract and its purified active compound are effective at a lower dosage as a medicine for many health disorders such as fatigue, stress or anxiety, depression, sleep deprivation, life-threatening psychiatric diseases etc. A solid delivery system of Withania somnifera composition or its purified active compound withanoside X is made of a core, the core is characterised by a solid bead, and a layer of Withania somnifera extract or purified compound Withanoside X covering said solid bead Over the extract another layer of a protective system is provided to seal the composition in it. The protective system also protects the composition from the acidic environment of the stomach when administered orally. The solid dosage form of withanoside X is characterized with at least about 95% withanoside X. The solid dosage form of Withania somnifera composition is characterized by about 2% to about 80% withanolide glycoside.

Beadlets is preferred because of the smooth and uniform surface. The Withania somnifera extract can be made into a beadlets form or can be uniformly layered over beadlet. Because of the uniform surface or layering, the quantity of protective system required is also lowered.

Materials suitable for use as beads are saccharides such as Sugars, oligosaccharides, polysaccharides and their derivatives, for example, glucose, rhamnose, galactose, lactose, sucrose, mannitol, sorbitol, dextrin, maltodextrin, cellulose, Sodium carboxymethyl cellulose, starches (maize, rice, potato, wheat, tapioca) and the like saccharides.

The excipients used along with Withania somnifera extract for layering over beadlet are Hydroxyl propyl methyl cellulose (HPMC), Synthetic polymers, Shellac, Corn protein Zein, Polysaccharides, Ethyl cellulose, Talc, Stearic acid, Magnesium stearate, Calcium stearate, Polyethylene glycol (Macrogol), Polyvinyl pyrrolidone K30 (PVP K30), Surfactants, vegetable oil.

The size of the solid delivery system of Withania somnifera composition or withanoside X is about 0.15 to 0.6 mm. For oral administration, a solid delivery system in beads form is more bioavailable compared to a tablet.

The Withania somnifera extract is obtained from Withania somnifera whole plant or fresh root or dried root, stem or leaves, green berries, fruits, seeds, the bark of Withania somnifera or their combinations.

Administration of dosage form of Withania somnifera composition or purified compound withanoside X have shown the following activities: viz. immunomodulatory activity, activity towards lowering depression and anxiety, helps in sleep disorder, increases testosterone in male, and improves endurance. The solid delivery system of Withania somnifera composition containingwithanoside X is used in the treatment of depression, anxiety and sleep disorder. The solid delivery system of Withania somnifera composition or withanoside X is administered at a dosage of lOmg to 2000mg to a human subject to treat depression and anxiety and sleep disorder. The solid delivery system of Withania somnifera composition or withanoside X is administered to increase testosterone in male, and improve endurance in human subjects.

In some embodiments, the Withania somnifera extract, withanolide glycosides are at least about 2% to about35%. More preferably, Withania somnifera extract is standardised with 2% to 35% withanolide glycoside by weight.

In some embodiments, the Withania somnifera extract has withanoside X ranges from about 0.5% to about 10%. More preferably withanolide glycoside is standardised with at least 0.5- 10% withanoside X. In some embodiments of the Withania somnifera extract, withanoside X is at least about 0.5% or about 6%. More preferably withanolide glycoside is standardised with at least 0.5-6% withanoside X.In some embodiment, purified compound withanoside X from Withania somnifera is at least about 95%. More preferably, Withania somnifera extract is standardised up to 95% withanoside X. In some embodiment of protective Withania somnifera composition, withanolide glycoside in the dose form is 5% to 20%. In some embodiment of protective Withania somnifera composition, withanolide glycoside in the dose form is 13.1%.

Some embodiments provide a dosage form of the purified extract of Withania somnifera, including capsule, tablet, mini-tablet, granule, powder, ampoule, or pills. The delivery systems may require excipients selected from the group consisting of a disintegrant, diluents, binders, fillers, a carrier, adsorbents, emulsifiers, lubricants, stabilizing agents, antiadherents, galidants, antioxidants and mixtures thereof.

The delivery system of withanoside X in the dosage form is about 10 mg to about 2000 mg. The disclosure provides a stable Withania somnifera extract enriched with withanoside X prepared by a novel process. The disclosure also provides a process of making the solid dosage form.

The method of preparing an extract of Withania somnifera includes cleaning roots and leaves of Withania somnifera, followed by extracting the leaves and roots with methanol at about 60°C to about 70°C to obtain a supernatant and a residue. Separate the supernatant from residue and concentrate the supernatant to obtain a concentrate. Next, drying the concentrate to get a powdered methanol extract, it shall be referred to as sample 1.

The powdered methanol extract (sample 1) is fractionated by using a flash chromatographic system. Powdered methanol extract is impregnated with silica gel in 1: 1 ratio. The impregnated methanol extract is transferred into a sample of a cartridge in a flash chromatograph and column is initially eluted with 2 column volume (CV) of water followed by gradient elution with 2 column volume of 0-20% acetonitrile. After that column eluted with two times the column volume of 20% acetonitrile, after that, two times the column volume of 20-30% acetonitrile followed by three times the column volume of 30-70% acetonitrile and two times the column volume of 70-100% acetonitrile, and finally column is eluted with 3 column volume of 100% acetonitrile. First eluted eight-column volume was collected as fraction 1, and next eluted 8 column volume is collected as fraction 2 (sample 3).

Purified compounds are isolated from sample 3 by semi -preparative HPLC system. The major compound that eluted at retention time (RT) 44 min is collected after repeated injection of sample 3 into a semi -preparative HPLC system. All the fractions from different injections are pooled and concentrated to dryness under vacuum to form a powder of purified compound, withanoside, with more than 95% purity. The purified molecule is further subjected to NMR and HRMS analysis for its structure elucidation. The compound is isolated as an amorphous powder.

In one embodiment method of preparing an extract of Withania somnifera includes cleaning roots and leaves of Withania somnifera, followed by extracting the leaves and roots with methanol at about 60°C to about 70°C to obtain a supernatant and a residue. Separate the supernatant from residue and Concentrate the supernatant to obtain a concentrate. Next, drying the concentrate to obtain a powdered methanol extract, it shall be referred to as sample

1.

Powdered methanol extract is dissolved in water and clarified to form supernatant and residue. The supernatant is loaded on a resin column and initially eluted with 20-25% methanol, followed by 75% methanol. 75% of methanol elute is collected. 75% methanol fraction is concentrated in an Agitated thin film evaporator (ATFE) to form concentrated methanol extract. Concentrate fraction was fed into vacuum stripper and dried under vacuum at above 500 mm of mercury to get powder of 75% methanol extract of Withania somnifera.

The method for making the delivery system includes preparing a layer of Withania somnifera extract or its purified compound over beadlets and over the extract layer a layer of protective system is applied, this material seals the extract. Beadlets may then be filled into capsules or shells, such as gelatin capsules for ease of swallowing. The extract of Withania somnifera has at least about 35% withanolide glycosides, and withanoside X makes up at least about 6% of withanolide glycosides. Some embodiments the purity of withanoside X in the delivery system go up to 95%.

The protective system can be Methacrylic acid co-polymers, poly (methacrylic acid co-methyl methacrylate) 1: 1, poly (methacrylic acid co-methyl methacrylate) 1 :2, poly (methacrylic acid co- ethyl acrylate) 1 : 1, poly (methyl methacrylate-co-methacrylic acid), Cellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PVAP), shellac, Cellulose acetate trimellitate (CAT), Hydroxypropyl methylcellulose phthalate (HPMCP).

To improve the efficacy of the delivery system a specific protective system suitable for Withania somnifera extract can be formulated by combining one or more components selected from alginate, pea starch, and beta-acacia.

The protective system also includes plasticizers for enhancing the film-forming property. Commonly used plasticizers are polyethylene glycols PEG, propylene glycol, glycerol (glycerin), phthalate esters, dibutylsebacete, fractionated coconut oil and acetylated monoglycerides . Most of the protective system known in the art are acidic in nature and hence may cause chemical instability when in contact with acid labile ingredients. To minimize this acid caused instability, a sub coat is usually applied between the particles, beadlets, pellets, etc., and the protective system. This sub coat physically separates the acid labile drug from the acidic protective system, and hence improves the stability of the formulation. This sub coat also increases the mechanical strength of beadlets. Sub coat materials can be hydroxyl propyl methyl cellulose (HPMC), ethyl cellulose, hydroxpropylcellulose, hydroxymethyl cellulose and cellulose acetate phthalate.

The solid delivery system of the present invention contains Withania somnifera extract or its purified compounds as the active material, Methacrylic acid co-polymers as a protective system, polyethylene glycol as a plasticizer, hydroxyl propyl methyl cellulose as sub coat and Sugar beadlets as a core material.

The delivery system of Withania somnifera composition comprises of 80 part methanol extract of Withania somnifera, 4.2 part HPMC, lpart talc by weight. The protective system of the present invention disintegrates or dissolves at the pH commonly found in the small intestine. The pH-solubility behaviour of the protective system of the present invention is such that significant dissolution of the protective system will not occur until the dosage form has emptied from the stomach. The pH of the small intestine gradually increases from about 4.5 to about 6.5 in the duodenal bulb to about 7.2 in the distal portions of the small intestine (ileum).

Antidepressant activity of the protective composition of Withania somnifera extract is described in the following embodiment.

Forced swim test (FST) model was used to evaluate antidepressant activity. Reserpine was injected i.p. to all the rats to depress the animals except normal control group. Normal saline was injected to the rats of the normal control group. After 3 hours of reserpine injection, the test samples/standard was fed orally as the designated dose. After 1 hour of test sample/standard, the rats were tested using a forced swim test and duration of immobility in the 5 minutes test session was recorded. When compared to untreated (depressed) control rats, the protective composition of Withania somnifera at lower dosage has reduced the immobility period to an almost normal level. The isolated compound (withanoside X) produced antidepressant effects at a very low dose in rats.

In some embodiment, the protective dose form of Withania somnifera extract and its purified compound is tested in human subjects, and found to have useful for sleep disorders, enhancing endurance, old age rejuvenation, immunomodulatory effects, and it is substantiated by carrying out the following studies.

Testosterone study:

A double-blinded randomized placebo controlled cross over the trial to evaluate the effect of the protective composition of Withania somnifera extract and its purified compound on salivary hormones, and symptoms of fatigue and vitality in healthy, overweight men were carried out. Withania somnifera extract was administered in a dosage which delivers 21mg withanolide glycoside /day for eight weeks.

In week 8, Ageing Males’ Symptoms (AMS) self-report measure, Profile of Mood States, Short Form (POMS-SF); fatigue-inertia and vigor-activity subscale scores and salivary testosterone, cortisol, DHEA-S, and oestradiol were analysed. After 8 weeks, the subjects were crossed-over to other intervention. Protective composition of Withania somnifera extract was administered for 16 weeks in a dosage delivers 21 mg withanolide glycoside /day. In week 16, AMS, POMS-SF, fatigue-inertia and vigour-activity subscale scores and salivary testosterone, cortisol, DHEA-S, and oestradiol were analysed.

The Aging Males' Symptom (AMS) scale allows for a more quantitative assessment of testosterone deficiency (TD). The AMS can confirm the presence of symptoms that are associated with low testosterone such as diminished erections, low desire, flushing and sweating. The AMS can also help differentiate the primary cause of erectile dysfunction, e.g. low testosterone versus vascular issues.

AMS is a 17-item, self-report questionnaire measuring psychological, somatic, and sexual symptoms. Items are rated on a 5-point Likert scale from 1 (none) to 5 (extremely severe). The AMS is a commonly-used and reliable/valid measure of ageing symptoms in men, and their impact on the quality of life (Daig et ah, 2003).

AMS scoring (total score):

< 26 means no significant symptoms consistent with a low testosterone level. 27-36 means mild symptoms consistent with a low testosterone level.

37-49 means moderate symptoms consistent with a low testosterone level.

> 50 means severe symptoms consistent with a low testosterone level.

The AMS was completed at baseline, week 4, week 8, week 12, and week 16 after the commencement of dosage intake. A statistically significant 42% reduction in AMS score is observed over time in the protective composition group.

The POMS-SF is a 35-item, self-report questionnaire with subscales including Anger- Hostility, Confusion-Bewilderment, Depression-Dejection, Fatigue-Inertia, Tension-Anxiety, Vigor- Activity, and Friendliness. Items are rated on a 5 -point Likert scale from 0 (not at all) to 4 (extremely). The POMS-SF is a commonly-used and reliable/valid questionnaire (Heuchert and McNair, 2012) with the fatigue-inertia subscale demonstrating good validity in a patient population (Fink et ah, 2010). The POMS-SF fatigue-inertia and vigour-activity subscale standardized scores were used to examine symptomatic change over time. Statistically significant 60% reduction in POMS Fatigue-Inertia score and 85% increase in POMS Vigor- Activity score is observed over time in the protective composition group. 8-week intake of Withania somnifera protective composition which delivers 21mg withanolide glycoside was associated with significant improvement in salivary DHEA-S and testosterone. In a group administered with Withania somnifera protective composition, significant improvement in DHEA-S level and testosterone level compared to the placebo group were noticed. A significant improvement over time in levels of vigour and emotional or sexual wellbeing from Withania somnifera supplementation was observed. Level of cortisol was decreased by 42%, and DHEA-S is increased by 43% in the protective composition group.Testosterone level is increased by 52% in protective composition group. There was no change in Estradiol level after administering the protective composition. An improvement was observed in AMS total score and POMS vigour activity score in Withania, somnifera supplementation group.

Anti-anxiety study: A randomized, double -blind, placebo-controlled study evaluating the efficacy, safety, tolerability, and pharmacological actions of a Withania somnifera protective composition was done in healthy, stressed adult volunteers. Healthy subjects with a total score between 6 to 17 on the Hamilton Rating Scale of Anxiety were given Withania somnifera extract protective composition in a dosage delivers 21mg withanolide glycosides, for 60 days. Hamilton Anxiety Rating Scale (HAM-A), Depression Anxiety Stress Scale (DASS-21), blood cortisol, DHEA-s levels and testosterone levels were analysed. Changes in the cortisol/DHEA-S ratio were also calculated.

Hamilton Anxiety Rating Scale (HAM-A): The HAM-A is a widely used, well-validated tool consisting of 14 items designed to assess the severity of a patient’s anxiety 13. In this clinician-rated measure, each of the 14 items is rated on a 5-point scale, ranging from 0 = not present to 4 = severe. The HAM-A was completed at initial assessment (7-days prior to capsule administration) and 15, 30, 45, and 60 days after commencement of test sample intake.

Depression, Anxiety, Stress Scale -21 (DASS-21): The DASS-21 is a validated self-report measure assessing symptoms of stress, anxiety, and depression 14. Twenty-one questions are rated on a 4-point scale (0 to 3), ranging from never to almost always. The DASS-21 was completed at initial assessment (7-days prior to testing sample administration) and 15, 30, 45, and 60 days after commencement of test sample intake.

There was a significant improvement in total score on Hamilton Anxiety Rating Scale (HAM- A), improvement in total score and subscale scores on the Depression Anxiety Stress Scale

(DASS-21), reduction in morning blood cortisol, DHEA-s levels, the ratio of cortisol/ DHEA- s levels and improvement in testosterone levels within 30days. A statistically significant 41% reduction in HAM-A is observed over time in the protective composition group. Statistically significant 50% reduction in DASS-21 is observed over time in the protective composition group.

Sleep study:

A randomized, double -blind, placebo-controlled study is for evaluating the effects of Withania somnifera protective composition on Non-Restorative Sleep (NRS). Withania somnifera protective composition was administered for six weeks in a dosage delivers 21 mg withanolide glycoside /day. Efficacy of the extract is assessed in NRS patients by evaluating total score of Restorative Sleep Questionnaire-weekly version (RSQ-W), Actigraphy parameters (Average number of awakenings per hour of sleep, Average total sleep time in one week, Sleep efficiency), Nocturnal Polysomnogram (NPSG) parameters (Sleep Onset Latency (SOL), Wakefulness after Sleep Onset (WASO), Total Sleep Time (TST), Micro arousal Index, Time spent in individual Sleep Stage), Quality of life scores using WHOQOL- BREL scale, Depression and anxiety scores using Hospital Anxiety and Depression Scale (HADS), C-reactive protein levels. Restorative Sleep Questionnaire (RSQ-W) Total Score: RSQ-W is a validated scale for measuring the refreshing quality of sleep. It has nine items with answers scaled from 1 to 5. Some items are reversed scored. The total score is an average score based on all nine items and rescaled to a 0-100 scale, using the following transformation:

RSQ-W Total Score = (RSQ-W average score across completed items - 1) X 25. An improvement in RSQ-W score was observed after administration of Withania somnifera protective composition.

WHOQOL-BREL Scores: WHOQOL-BREL is a 26-item, self-administered, cross-culturally validated questionnaire in which items are rated on a 5 -point scale. The 26 items measure the following broad domains: physical health, psychological health, social relationships, and environment. Domain scores are scaled in a positive direction (i.e. higher scores denote a higher quality of life). The mean score of items within each domain is used to calculate the domain score. Mean scores are then multiplied by 4. The second transformation method described in the manual converts domain scores to a 0-100 scale. An improvement in WHOQOL-BREF Scores was observed after administration of Withania somnifera protective composition.

Hospital and Anxiety Scale (HADS) Score: HADS is a 14-item cross-culturally validated scale with seven items each in two subscales for evaluation of symptoms of anxiety (HADS- A) and depression (HADS-D). It detects symptoms of anxiety and depression, rather than making a diagnosis of the syndrome, and excludes symptoms that may arise from physical illness, insomnia, or fatigue. Each item is scored (0 to 3) according to severity, with a maximum possible score of 21 for each subscale. A score of 0 to 7 indicates no anxiety or depression, a score of 8 to 10 indicates a borderline case, and a score of 11+ indicates the presence of anxiety and/or depression. An improvement in HADS score was observed after administration of Withania somnifera protective composition.

Actigraphy Parameters: Actigraphy is a non-invasive method of monitoring human rest/activity cycles. It is validated against gold standard Nocturnal Polysomnogram. A small actigraphic unit, also called an actimetry sensor, is worn on the wrist for a week or more to measure gross motor activity. Using Tri-axial accelerometry principle, values are acquired in the memory. ZCM (zero crossing mode) counts the number of times the accelerometer waveform crosses 0 for each time period. PIM (proportional integral mode) measures the area under the curve and adds that size for each time period. TAT (time above threshold) uses a certain threshold and measures the length of time that the wave is above a certain threshold. An improvement in Actigraphy parameters was observed after administration of Withania somnifera protective composition.

Nocturnal Polysomnography (NPSG) Parameters: NPSG is considered a gold standard test for objective measurements of sleep parameters such as Total bedtime, total sleep time, sleep efficiency, sleep onset latency (SOL), wakefulness after sleep onset (WASO), micro arousal index, % of each sleep stage (NREM stage 1,2 and 3 and REM), Apnea/Hypopnea index (AHI), Periodic limb movement index (PLMI). The parameters are defined as below:

• Sleep Onset Latency [SOL] (minutes): Defined as time from lights out to onset of sleep.

• Wake After Sleep Onset [WASO] (minutes): Defined as total time awake until final wake time after sleep onset. Total Sleep Time in minutes: total time in bed - (WASO + SOL)

• Sleep Efficiency [SE] (%): Defined as the ratio of total sleep time to total time in bed •Time spent in particular sleep stages [NREM stage 1, 2 and 3, as well as REM] (minutes)

• Micro arousal index (number/hour): Total number of micro arousals as per the scoring criteria are given by the AASM divided by total sleep time (TST) measured in hours.

The NPSG monitors, many body functions including brain (EEG), eye movements (EOG), muscle activity or skeletal muscle activation (EMG) and heart rhythm (ECG) during sleep. Recordings will be taken from bedtime to awakening in the morning and continuous audiovisual IR monitoring of the subjects. Sleep stages shall be manually scored according to guidelines in the American Academy of Sleep Medicine (AASM) Manual for the Scoring of sleep and associated events in 30sec epoch page. An improvement in Nocturnal Polysomnography Parameters was observed after administration of Withania somnifera protective composition.

Serum C - reactive protein levels (CRP): Serum CRP, a systemic marker of inflammation that is associated with increased risk for a host of chronic diseases. Reduction in the CRP level would suggest a reduction in chronic inflammation. A significant improvement in CRP level is noticed after administration of Withania somnifera protective composition for six weeks in a dosage which delivers 21 mg withanolide glycoside /day.

Immunomodulatory study: A double-blinded randomized placebo controlled trial for immune-modulatory effects of Withania somnifera protective composition on healthy adult volunteers was done in a dose delivers 21 mg withanolide glycoside /day for 30days. After 30 days, the same participants were administered only protective composition of Withania somnifera extract. Parameters analyzed were cytokines Thl (interferon-g) and Th2 (interleukin-4), Immunoglobulin assay of IgG, IgM and IgA, Phenotyping of Lymphocytes (TBNK) - T-cells (CD3+ CD4+, CD8+), B- cells (CD19+) and NK-Cells (CD16+, CD56+) and serum cortisol. There was a significant increase in the Thl and Th2 cytokines after 30days of Withania somnifera protective composition administration along with a significant increase in T-helper cells and NK-cells. Improvement in immune-modulating activity includes an increase in IgG, IgM and IgA value, increase in TBNK cell counts, and a decrease in serum cortisol.

Endurance study:

Effects of both acute and short-term oral Withania somnifera intake on performance and rate of perceived exertion in the high-intensity aerobic and anaerobic exercise was studied.

Healthy male subjects were recruited for voluntary participation in this study. The study involves two phases, with a total of 5 identical test sessions. Each test session involves a maximal incremental cycling test followed by a 90-sec maximal cycling performance test (day 1), and a 30-min simulated time-trial on a cycling ergometer (day 2). Day one and day two are separated by a 24hr rest interval and for each subject were consistently scheduled on the same time of the day to eliminate a potential impact of diurnal variation in the results.

The acute effects of Withania somnifera protective composition were investigated in phase 1 of the study (sessions 1 and 2) Sessions 1 and 2 were separated by a 1-week interval. According to a randomized placebo-controlled double-blind crossover study design the subjects receive either Withania somnifera (WS) or placebo (PL) 60 min before the start of the incremental V02max test on day 1, and the 30-min time-trial on day 2. In session 1, half of the subjects receive WS whilst the others receive PL. Treatments were switched in session 2.

The short-term effects of WS were investigated in phase 2 of the study (sessions 2-3-4-5). Phase 2 involves two 14-day supplementation periods (WS vs PL) with a 2-week washout period in between and according to a randomized placebo-controlled double -blind crossover study design. Immediately after session 2, the subjects who were receiving WS in session two start the 2- week WS supplementation period, whilst the others continue PL for two weeks. Session 2 serves as the baseline for the 1st short-term supplementation period (pretestSTl). At the end of the 2-week supplementation period, the subjects participate in session 3 (posttestSTl), which is followed by a2-week washout period without any supplementation. After the washout period and according to the crossover study design, the subjects participate in session 4 (pretestST2), yet subjects start the other treatment than in period 1 (WS vs PL). At the end of the supplementation period, they participate in session 5 (posttestST2). Similar to sessions 1 and 2, in sessions 3-4-5 the subjects ingest either WS or PL both 60 min before the start of the incremental V02max test (day 1) and 60 min before the start of the 30-min time-trial (day 2).

An improvement in performance 30 min simulated time trial on a cycling ergometer, rate of perceived exertion 15-point Borg scale, oxygen intake (V02 max) and capillary blood lactate from earlobes after the consumption of Withania somnifera protective composition.

Example 1

Method of extracting Withania somnifera purified extract and Isolation of amorphous powder of withanoside X from roots and leaves of Withania somnifera: 100 Kg of fresh roots and leaves of Withania somnifera were collected. Roots and leaves were cleaned with water and flaked. The flaked roots and leaves were extracted with 60% methanol (300 L) at a temperature of 60-70°C for one hour to obtain a first residue and first supernatant. The first residue was then further extracted two more times with three times the quantity of 60% methanol each time. The residue and supernatants were separated. All the supernatants were pooled and concentrated in an agitated thin film evaporator (ATFE) to form a concentrated methanol extract. The concentrated methanol extract was dried under vacuum at above 500 mm of mercury to get powder of 60% methanol extract of Withania somnifera (yield 15 kg)(sample 1).

Sample 1 was further fractionated by using a flash chromatographic system. C18 silica gel particles of size about 40-63 pm are loaded into a KP-SIL100g SNAP cartridge, and the column was primed (wet) with water. Before loading to the column, sample 1 was impregnated with silica gel in 1 : 1 ratio. The impregnated sample 1 was transferred into the samplet of the cartridge in a flash chromatograph. After sample loading, the column was initially eluted with 2 column volume (CV) of water followed by gradient elution with 2 column volume of 0-20% acetonitrile. After that column eluted with 2 column volume of 20% acetonitrile, 2 column volume of 20-30% acetonitrile followed by 3 column volume of 30- 70% acetonitrile and 2 column volume of 70-100% acetonitrile. Finally, the column was eluted with 3 column volume of 100% acetonitrile. First eluted eight-column volume was collected as fraction 1 (yield 53%, sample 2) and next eluted 8 column volume was collected as fraction 2 (yield 47%, sample 3). Sample 3 contains 35% withanolide glycoside and 6.3% withanoside X. Percentage of withanoside X present in sample 3 was estimated by HPLC. The process was explained in FIG 1 (Part 1 and 2).

Purified compounds were isolated from sample 3 by semi-preparative HPLC system (LC 20AP) equipped with a PDA detector (SPD M20A) and a fraction collector (FRC 10A).

Compounds were separated on a Semi Prep Enable C18 column (lOu, 250X20mm) maintained at room temperature. Elution was carried out with a gradient system composed of two solvents viz, Solvent A (Water) and Solvent B (Acetonitrile). Compounds were collected with the aid of a fraction collector. The major compound that gets eluted at RT (retention time) 44 min was collected after repeated injection of sample 3 into semi -preparative HPLC system. All the fractions from different injections were pooled. The pooled fraction was repeatedly injected into the semi preparative HPLC for final purification, and the purified fraction was collected at each injection. Purified fractions from different injections were pooled and concentrated to dryness under vacuum to form a powder of purified compound, withanoside X, with more than 95% purity. The purified molecule was further subjected to NMR and HRMS analysis for its structure elucidation. The compound was isolated as an amorphous powder.

Example 2 Method of preparing bioactive ingredient protective system of Withania somnifera composition a. Method of layering of Withania somnifera on a sugar beadlets.

8 Litre of purified water was taken and kept for stirring under a mechanical stirrer. 105 gm of hydroxyl propyl methyl cellulose (HPMC) and 25 gm Talc were added slowly to water to form a uniform suspension. 2Kg of Withania somnifera extract (Prepared as per example 1) was accurately weighed and added to the suspension with constant stirring for 30 mins. 1936gm sugar beadlets were coated with the prepared drug suspension using Fluidized Bed Coater (FBC, 300 kg capacity, three spray gun, fully automatic type) to get 110% coating of the extract on the sugar beadle ts. b. Process of sealing of Withania somnifera layered on a sugar beadlets:

406 gm of HPMC was dissolved in 3.66 L of purified water (10% TDS solution) and kept for stirring under a mechanical stirrer. Stirring was continued for 30 minutes. Withania somnifera extract layered sugar beadlets were coated with the coating solution using Fluidized Bed Coater (FBC). c. Process of preparing a protective system of Withania somnifera layered on a sugar beadlets :

1565g of Methacrylic acid co-polymer with 30% TDS was added to 14.09 L of purified water to prepare a 10% TDS solution and kept for stirring for 30 minutes under a mechanical stirrer. An aqueous solution of polyethylene glycol with 20% TDS was added to Methacrylic acid co polymer solution and mixed by stirring under a mechanical stirrer for 30 minutes. The aqueous solution of polyethylene glycol with 20% TDS was prepared by dissolving 201gm of polyethylene glycol in 805ml of purified water and kept for stirring under a mechanical stirrer for 30 minutes. Withania somnifera extract seal coated sugar beadlets were layered with the coating solution using Fluidized Bed Coater (FBC) to get a protective system of Withania somnifera with 15% coating.

Method of preparing bioactive ingredient protective system of Withania somnifera composition was represented in FIG 2. Example 3

100 kg of roots and leaves of Withania somnifera were collected and cleaned. Cleaned plant parts were extracted with 60% methanol. Plant parts were refluxed with 300L of 60% methanol at the boiling temperature (60-70°C) of methanol for one hour to obtain a residue and supernatant. The residue was then further extracted two more times with three times the quantity of methanol at each time. The residue and supernatants were separated. All the supernatants were pooled and concentrated in an Agitated thin film evaporator (ATFE) to form a concentrated methanol extract. The concentrated methanol extract was dried under vacuum at above 500 mm of mercury to get powder of 60% methanol extract of Withania Somnifera with 10% yield. (Samplel).

10 Kg of sample 1 was dissolved in water and clarified to form supernatant and residue. The supernatant was loaded on a resin column. After passing the supernatant through the column, the column was initially eluted with 20-25% methanol followed by 75% methanol. 75% of methanol elute was collected. 75% methanol fraction was concentrated in an Agitated thin film evaporator (ATFE) to form concentrated methanol extract. Concentrate fraction was fed into vacuum stripper and dried under vacuum at above 500 mm of mercury to get powder of 75% methanol extract (sample 2a)(yield 8%) of Withania somnifera with 8% yield. The powder of 75% methanol fraction of Withania Somnifera was standardized with 35% withanolide glycosides.

Method of preparing the Withania somnifera extract is represented in FIG 3 (part 1 and 2).

Example 4

Sixty rats were randomly divided into ten groups comprising of 6 rats in each group. Extract/standard drug/vehicle was administered orally to the respective group of animals as per Table 1. After one h, reserpine (6 mg/kg) was injected i.p. to all the rats except Group 1. Normal saline (1 ml/kg; i.p.) was injected to the rats of group 1. The test session was started three hours after the injection of reserpine and total duration of immobility in test session (5 min duration) was noted. After completing the study, the animals were rehabilitated in the animal house.

Table 1. Animals grouping and treatment for the forced swim test.

Table 2. Immobility time of rats in the forced swim test.

As shown in the Table 2, immobility time for normal control animals was 121 seconds. When reserpine was injected i.p., the animals got depressed, and immobility time was increased to 220 seconds (Group II). Oral administration of Withania somnifera extract with 7% withanolide glycosides at 60mg/kg dosage after reserpine injection was not much effective and immobility time was recorded as above 210 seconds (Group IV). But in group V, coated Withania somnifera extract with 7% withanolide glycosides after reserpine injection, the immobility time was recorded as 170 seconds. The immobility time was found as 155 seconds when animals were treated with purified Withania somnifera extract with 35% withanolide glycosides at 60 mg/kg dose (Group VI). The same extract after coating at a lower dosage (lOmg/Kg) has reduced the immobility period to almost normal level (125 seconds). The isolated compound, sample 4 (Withanoside X) coated produced antidepressant effects at a very low dose of 2.5 mg/kg in rats. The immobility time was 90 seconds while administering coated sample 4. Sample 4 without coating at lOmg/kg also showed an immobility time of 115 seconds and sample 4 coated results an immobility time of 90 seconds at a lower dosage of 2.5mg/Kg.

Example 5

A 16 week double-blinded randomized placebo controlled cross over trial to evaluate the effect of the protective composition of Withania somnifera extract and its purified compound on hormones by analyzing the saliva and symptoms of fatigue and vitality in healthy, overweight men were carried out. Withania somnifera extract was administered in a dosage which delivers 21mg withanolide glycoside /day for eight weeks. No washout period was included in this crossover trial as the aim in the second period of the trial was also toinvestigate the durability of changes after discontinuation of the active treatment.

Participants were randomly and equally allocated into two groups (placebo followed by a protective composition of Withania somnifera extract or protective composition of Withania somnifera extract followed by placebo). Parameters analyzed are Aging Males’ Symptoms (AMS) self-report measure, Profile of Mood States (POMS-SF); Fatigue- Inertia and Vigor- Activity subscale scores, salivary testosterone, cortisol, DHEA-S, and estradiol. A statistically significant 42% reduction in AMS score was observed over time in the protective composition group. Statistically significant 60% reduction in POMS Fatigue-Inertia scoreand 85% increase in POMS Vigor- Activity score was observed over time in the protective composition group. Results are represented in FIG. 4. Level of cortisol was decreased by 42%, and DHEA-S was increased by 43% in the protective composition group. Results are represented in FIG.5. Testosterone level was increased by 52% in protective composition group. There was no change in Estradiol level after administering the protective composition. Results are represented in FIG. 6.

Example 6 A 60-day, randomized, double-blind, placebo controlled trial for evaluating the efficacy and tolerability of protective composition of Withania somnifera extract on stress, anxiety, and hormone production in healthy adults. Subjects were divided into two groups, and baseline outcome measures were collected including a morning blood sample (to assess DHEA-S, cortisol, and testosterone), clinician-administered Hamilton Anxiety Rating Scale (HAM-A), and self-report Depression, Anxiety, Stress Scale-21 (DASS-21). Protective composition of Withania somnifera extract and placebo were given to subjects for 60 days. On day 30 and 60 blood samples were collected to assess for cortisol and DHEA-S. Assessment of testosterone levels was only undertaken at baseline and day 60.

A statistically significant 41% reduction in HAM-A was observed over time in the protective composition group. Statistically significant 50% reduction in DASS-21 was observed over time in the protective composition group. Results are represented in FIG. 7.

In the protective composition group, a statistically significant 50% reduction in cortisol was observed over time. A statistically significant 49% increase in DHEA-S was observed over time after administering a protective composition of Withania somnifera extract. 52% increase in testosterone was observed over time in the protective composition group. Results are represented in FIG. 8.

Protective composition of Withania somnifera extract intake was associated with a statistically significant, greater reduction in the HAM-A and DASS-21. Based on the HAM- A, anxiety levels reduced by 41% in participants taking protective composition. Further confirmation of the mood-enhancing effects of the protective composition was provided by positive overall improvements in the DASS-21, a measure of depressive, anxiety, and stress symptoms. Example 7

A randomized, double -blind, placebo-controlled study is for evaluating the effects of Withania somnifera protective composition on Non-Restorative Sleep (NRS). Withania somnifera protective composition was administered for six weeks in a dosage delivers 21 mg withanolide glycoside /day. Efficacy of the extract is assessed in NRS patients by evaluating total score of Restorative Sleep Questionnaire-weekly version (RSQ-W), Actigraphy parameters (Average number of awakenings per hour of sleep, Average total sleep time in one week, Sleep efficiency), Nocturnal Polysomnogram (NPSG) parameters (Sleep Onset Latency (SOL), Wakefulness after Sleep Onset (WASO), Total Sleep Time (TST), Micro arousal Index, Time spent in individual Sleep Stage), Quality of life scores using WHOQOL- BREL scale, Depression and anxiety scores using Hospital Anxiety and Depression Scale (HADS), C-reactive protein levels.

The results represented in LIG. 9indicate that the protective composition of Withania somnifera extracts improved the quality of sleep as compared to placebo. There was 72% mean increase in the quality of sleep in the protective composition group. Within the group analysis in protective composition group gave very strong evidence that protective composition increased the TST and SE significantly, and it was represented in LIG.10. There was a statistically significant decrease in SOL, WASO and average awakening time in protective composition group compared to the corresponding initial period (LIG.11). Between the group, the analysis indicated that at baseline, there was no significant difference between protective composition and placebo groups in all actigraphy parameters. At the end of the study, the protective composition of Withania somnifera group showed a significant increase in TST as compared to placebo. The SOL and WASO in Withania somnifera group was significantly less, and SE was significantly high as compared to the placebo group. This data indicates overall significantly better sleep quality in a protective composition group as compared to placebo.

The protective composition of Withania somnifera extract group had significant improvement in the domains of physical, psychological, and environmental dimensions. The percentage increase of score between day eight and day 50 in each domain was better in the protective composition of Withania somnifera extract group as compared to placebo. Results are represented as FIG. 12.

Claims

I Claim;

1. A delivery system for Withania somnifera composition derived from Withania somnifera extract in a dosage form comprises of;

a) a core, the core is characterised by a solid bead and a layer of Withania somnifera extract covering said solid bead,

and

b) a layer of protective system, over said core.

2. The delivery system as claimed in claim 1, wherein the dose form comprises 5% to 20% withanolide glycoside by weight.

3. The delivery system as claimed in claim 1, wherein said Withania somnifera extract is standardised with 2% to 35% withanolide glycoside by weight.

4. The delivery system as claimed in claim 3, wherein, withanolide glycoside is standardised with at least 0.5-10% withanoside X.

5. The delivery system as claimed in claim 3, wherein, withanolide glycosideis standardised with at least 0.5-6% withanoside X.

6. The delivery system as claimed in claim 1, wherein, Withania somnifera extract is standardised up to 95% withanoside X.

7. The delivery system as claimed in claim 1, wherein, the Withania somnifera composition comprises excipient selected from a group of Hydroxyl propyl methyl cellulose, polyvinyl pyrrolidone K30, polyethylene glycol, talc, magnesium state and combination thereof, and the excipients to Withania somnifera extract isin a ratio of 1:20 to 1 : 10.

8. The delivery system as claimed in claim 1, wherein, the Withania somnifera composition comprises of 80 part methanol extract of Withania somnifera, 4.2 part Hydroxyl propyl methyl cellulose, and lpart talc, by weight.

9. The delivery system as claimed in claim 1, wherein the solid bead is made of any one or more compound selected from glucose, rhamnose, galactose, lactose, sucrose, mannitol, sorbitol, dextrin, maltodextrin, cellulose, Sodium carboxymethyl cellulose, starches and a combination thereof.

10. The delivery system as claimed in claim 1, wherein the protective system is made of one or more material selected from the group of; Methacrylic acid co-polymers, poly (methacrylic acid co-methyl methacrylate), poly (methacrylic acid co-ethyl acrylate), poly(methyl methacrylate-co-methacrylic acid), Cellulose acetate phthalate, polyvinyl acetate phthalate, shellac, Cellulose acetate trimellitate, Hydroxypropyl methylcellulose phthalate, alginate, pea starch, beta-acacia and combination thereof.

11. The delivery system as claimed in claim 10, wherein protective system additionally contains plasticizer selected from a group of polyethylene glycols, propylene glycol, glycerol (glycerin), phthalate esters, dibutylsebacete, fractionated coconut oil, acetylated monoglycerides and combination thereof.

12. The delivery system as claimed in claim 1, wherein a sub coating layer is provided between the core and protective system.

13. The delivery system as claimed in claim 12, wherein the sub coating is selected from a group of hydroxyl propyl methyl cellulose, ethyl cellulose, hydroxpropylcellulose, hydroxymethyl cellulose, cellulose acetate phthalate, and combination thereof.

14. The delivery system as claimed in claim 1, wherein the protective system disintegrates or dissolves in pH 4.5 and above.

15. The delivery system as claimed in claim 1, wherein the solid beadlet is sugar beadlet, said beadlet is covered with Withania somnifera composition, the core is covered with hydroxyl propyl methyl cellulose to form a sealed core, and the sealed coreis covered with protective system comprising Methacrylic acid co-polymers.

16. The delivery system as claimed in claim 1, wherein the delivery system is a solid spheroidal, and the solid spheroidal is 0.15 to 0.6 mm.

17. The delivery system as claimed in claim 1, wherein the dosage form of lOmg to 2000mg is administered to a human subject for 4 to 8 weeks to see notable improvement in endurance, immunomodulatory activity, stress, anxiety, fatigue, depression, and sleep deprivation.

18. The delivery system as claimed in claim 17, wherein the improvement is based on Cortisol level, DHEA-S level, AMS, POMS, HAM-A, DASS-21, SC, TST, SOL, WASO, and RSQ-W scale.

19. A method of preparing Withania somnifera extract by fractionating a hydro-alcoholic extract of Withania somnifera plant parts to enrich withanolide glycoside, wherein the method comprisesofthe steps;

i. impregnating said hydro-alcoholic extract with silica gel in 1: 1 ratio, ii. transferring the impregnated extract in to a column

iii. eluting the column with 2 column volume (CV) of water,

iv. followed by, eluting the column with a two column volume of 0-20% acetonitrile,

v. followed by, eluting the column with two times the column volume of 20% acetonitrile,

vi. followed by, eluting the column with two times the column volume of 20-30% acetonitrile,

vii. followed by, eluting the column with three times the column volume of 30-70% acetonitrile,

viii. followed by, eluting the column with two times the column volume of 70-100% acetonitrile, and

ix. finally eluting the column with 3 column volume of 100% acetonitrile; and x. pooling together last eluted eight column volume to get an enriched withanolide glycoside extract.

20. The method as claimed in claim 19, wherein the hydro-alcoholic extract of Withania somnifera is a methanol extract.

21. A method of making the delivery system for Withania somnifera composition in a dosage form, wherein the method comprises of the steps;

a. spraying the Withania somnifera composition on to a fluidised solid bead lets to get a core,

b. the core is dried,

c. the dried core is fluidised, and

d. the resultant core is sprayed with the protective system till it cover the core completely.

22. The method of making the delivery systemas claimed in claim 21, wherein, the Withania somnifera composition comprises of 80 part methanol extract of Withania somnifera, 4.2 part HPMC, and lpart talc by weight.

23. The method of making the delivery system as claimed in claim 21, wherein the protective system comprises of Methacrylic acid co-polymer, polyethylene glycol and purified water.

24. The method of making the delivery systemas claimed in claim 21, wherein a sub coat is applied between the core and protective system.

25. The method of making the deliver system as claimed in claim 24, wherein the sub coating is selected from a group of hydroxyl propyl methyl cellulose, ethyl cellulose, hydroxpropylcellulose, hydroxymethyl cellulose, cellulose acetate phthalate, and combination thereof.